Pathogenesis and treatment of HIV lipohypertrophy

Current Opinion in Infectious Diseases

Volumn 24, Issue 1, 2011, Pages 43-49

  Leung, Vivien L ^a   Glesby, Marshall J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

HIV; lipodystrophy; lipohypertrophy; tesamorelin; visceral adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; GLUCOSE; GONADORELIN DERIVATIVE; GROWTH HORMONE; HYDROCORTISONE; LEPTIN; LOPINAVIR PLUS RITONAVIR; METFORMIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIOGLITAZONE; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT LEPTIN; RECOMBINANT SOMATOMEDIN C; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 3; STAVUDINE; TESAMORELIN; TESTOSTERONE; ZIDOVUDINE;

AEROBIC EXERCISE; ARTHRALGIA; ARTICLE; BODY FAT DISTRIBUTION; CARPAL TUNNEL SYNDROME; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXERCISE; FATTY ACID METABOLISM; GLUCOSE TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED LIPOHYPERTROPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPOHYPERTROPHY; LIPOSUCTION; METABOLIC DISORDER; METABOLISM; PATHOGENESIS; PERIPHERAL EDEMA; TREATMENT DURATION; TREATMENT OUTCOME;

GROWTH HORMONE-RELEASING HORMONE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HORMONES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78751514183     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283420eef     Document Type: Article

References (62)

1. Torriani M, Hadigan C, Jensen ME, Grinspoon S. Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol 2003; 95:1005-1010.
2. Lo J, Abbara S, Rocha-Filho JA, et al. Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS 2010; 24:2127-2130.
3. Blanch J, Rousaud A, Martinez E, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1.Clin Infect Dis 2004; 38:1464-1470.
4. Grunfeld C, Rimland D,GibertCL, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM Study. J Acquir Immune Defic Syndr 2007; 46:283-290.
5. Wohl D, Scherzer R, Heymsfield S, et al. The association of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008; 48:44-52. (Pubitemid 351600858)
6. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769-1778.
7. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119:812-819.
8. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-414.
9. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet 2004; 364:937-952. (Pubitemid 39208455)
10. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and antiretroviral therapy as predictors of sub-clinical atherosclerosis in human immunodefi ciency virus infected subjects. Atherosclerosis 2010; 208:222-227.
11. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39:395-400.
12. Dube MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007; 45:508-514.
13. ShikumaCM, Yang Y, Glesby MJ, etal. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 2007; 44:540-550.
14. Brinkman K, SmeitinkJA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
15. Shikuma CM, Hu N, Milne C. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-1809.
16. Kakuda T, Brundage R, Anderson P, et al. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity: an etiology for lipodystrophy. AIDS 1999; 13:2311.
17. Kratz M, Purnell JQ, Breen PA, etal. Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J Clin Endocrinol Metab 2008; 93:959-966.
18. Sekhar RV, Jahoor F, White AC, et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002; 283:E332-E337.
19. Sekhar RV, Jahoor F, Pownall HJ, et al. Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr 2005; 81:1405-1410.
20. Van Harmelen V, Lonnqvist F, Thorne A, etal. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int J Obesity Rel Metab Dis 1997; 21:972-979. (Pubitemid 27462400)
21. KinoT, Gragerov A, Kopp JB, et al. The HIV-1 virion-associated protein vpr is a coactivatorofthe human glucocorticoid receptor. J Exp Med 1993; 189:51-62.
22. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
23. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsuline-mia. J Clin Endocrinol Metab 2001; 86:1930-1935.
24. Addy C, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-636.
25. Fain JN, Madan JK, Hiler ML, etal. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145:2273-2282.
26. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999; 130:671-680.
27. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003; 36:795-802.
28. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus infected patients. Clin Infect Dis 1998; 27:68-72.
29. Sutinen J, Kannisto K, Korsheninnikova E, et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004; 47:1668-1671.
30. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294:2166-2170.
31. Veldhuis JD, Liem AY, South S, et al. Differential impact of age, sex-steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1995; 80:3209-3222.
32. Ghigo E, Procopio M, Boffano GM, et al. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism 1992; 41:560-563.
33. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86:504-510.
34. Koutkia P, Canavan B, BreuJ,Grinspoon S.Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab 2005; 90:32-38.
35. Koutkia P, Meininger G, Canavan B, et al. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286:E296-E303.
36. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000; 356:993-997.
37. Annaloro C, Usardi P, Airaghi L, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41:797-804.
38. Thoni GJ, Fedou C, Brun JF, et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 2002; 28:397-404.
39. Dolan SE, Frontera W, Librizzi J, et al. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch Intern Med 2006; 166:1225-1231.
40. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284:472-477.
41. Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004; 18:465-473.
42. Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 2007; 8:420-426.
43. Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006; 91:2605-2611.
44. Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with HIV-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009; 94:1137-1144.
45. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45:286-297.
46. Luzi L, Meneghini E, Oggionni S, et al. GH treatment reduces truncal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. Eur J Endocrinol 2005; 153:781-789.
47. Hansen BR, Haugaard SB, Jensen FK, et al. Long-term high-physiological- dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism. HIV Med 2010; 11:266-275.
48. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008; 300:509-519.
49. Falutz J, Allas S, Blot K, etal. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357:2359-2370.
50. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accu mulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010; 53:311-322.
51. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35:1219-1230.
52. Parker RA, Flint OP, Mulvey R, et al. Endoplasmic reticulum stress links dyslipidemiato inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005; 67:1909-1919.
53. Yan Q, Hruz PW. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 2005; 40:398-403.
54. Kim RJ, Wilson CG, Wabitsch M, et al. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity 2006; 14:994-1002.
55. Stanley TL, Joy T, Hadigan CM, et al. Effects of switching from lopinavir/ ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009; 23:1349-1357.
56. Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007; 21:47-57.
57. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010; 10:183.
58. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
59. Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007; 92:1049-1057.
60. Mauras N, Martinez V, Rini A, Guevara-Aguirre J. Recombinant human insulinlike growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000; 85:3036-3042.
61. Rao MN, Mulligan K, Tai V, et al. Effects of insulin-like growth factor (IGF)-I/ IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 2010; 95:4361-4366.
62. Hultman CS, McPhail LE, Donaldson JH, Wohl DA. Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plast Surg 2007; 58:255-263.